Experimental Novartis radiopharma drug shows promise in early study

Novartis reported early data showing anti-tumour activity from its experimental actinium-based prostate cancer drug, including in patients previously treated with Pluvicto. The update is an encouraging clinical signal for the company’s radiopharmaceutical pipeline, but it is still early-stage and does not yet confirm late-stage efficacy or regulatory success.

Analysis

Novartis reported early data showing anti-tumour activity from its experimental actinium-based prostate cancer drug, including in patients previously treated with Pluvicto. The update is an encouraging clinical signal for the company’s radiopharmaceutical pipeline, but it is still early-stage and does not yet confirm late-stage efficacy or regulatory success.